Breast Cancer Research
Whether you have early stage breast cancer or metastatic breast cancer, research can play an important role in your treatment plan, offering you access to leading-edge treatments. It can also play an important role in other peoples’ lives. By participating in a breast cancer clinical trial, you help pave the way to new prevention, detection and treatment strategies that can offer hope to people with cancer.
As an academic medical center, we are involved in some of the most groundbreaking cancer trials available today. By choosing the USC Breast Center for your breast care, you have access to clinical trials that are helping make breast cancer a disease of the past.
- Breast cancer breakthroughs
- Breast cancer clinical trials
- Finding a cure
- Improving detection, treatment, prevention
- National Cancer Institute (NCI) designation
- Understanding breast cancer causes
What our National Cancer Institute designation means
In 1973, USC Norris Comprehensive Cancer Center was designated as one of the country’s original eight comprehensive cancer centers by the National Cancer Institute (NCI), the federal government’s principle agency for cancer research and training. As an NCI-designated cancer center, we anchor the country’s cancer research efforts, making scientific discoveries that are translated into new treatments for people with cancer. The collective work of NCI researchers has led to important medical advances that have increased the number of cancer survivors in the United States and worldwide.
USC Norris cancer research breakthroughs
Our clinician-scientists have been at the forefront of cancer research for more than 40 years, making historic breakthroughs that have changed the way we understand breast cancer and how it’s treated.
Prone Partial Breast Irradiation (PBI): Prospective Randomized Controlled Non-inferiority Trial to Compare Radiation Fibrosis With Five Versus Three Fractions
Partial breast irradiation (PBI) is becoming a new paradigm for breast cancer radiation. No type I or II evidence is currently available to demonstrate equivalence to standard whole breast radiotherapy, ...Learn More ≫
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III
PRIMARY OBJECTIVES: I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving ...Learn More ≫
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Women with node positive breast cancer normally will receive endocrine therapy and some may receive chemotherapy to help prevent the cancer from coming back. Many women will also receive radiotherapy ...Learn More ≫
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
PRIMARY OBJECTIVE: I. To determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the control arm (T-DM1 + placebo) when ...Learn More ≫
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
PRIMARY OBJECTIVES: I. To compare the proportions of participants in the tomosynthesis mammography (TM) and digital mammography (DM) study arms experiencing the occurrence of an ?advanced? breast cancer at any ...Learn More ≫